FDA Expanded Access to Prostate Cancer Treatment
Patients with metastatic prostate cancer may now receive radiation-based therapy earlier in their treatment course.
Updated on Sept. 28, 2026 in Cancer
In the summer of 2026, the FDA expanded approval for Pluvicto, a targeted treatment that delivers radiation directly to cancer cells. This change allows patients in the United States to access this therapy sooner, rather than waiting until other treatment options have failed.
Why it matters
By moving this therapy earlier into the care sequence, the FDA aims to improve management for patients with metastatic disease. This regulatory shift reflects a growing medical preference for using molecular-guided treatments at earlier stages of cancer progression.
Clinical outcomes observed in individual patients, such as the 87-year-old patient Harlan Vanden Einde, demonstrate significant responses to the therapy. These findings highlight the potential efficacy of the treatment, though population-wide longitudinal trial results are still pending.
The players
BAMF Health
A medical facility based in Grand Rapids, Michigan, that specializes in molecular-guided imaging and advanced cancer treatments.
Harlan Vanden Einde
An 87-year-old patient diagnosed with metastatic prostate cancer who experienced a 95 percent reduction in disease burden following treatment.
Food and Drug Administration
The federal agency responsible for regulating medical devices and pharmaceutical therapies in the United States.
The details
Pluvicto utilizes organic chemistry to bind specifically to proteins expressed on the surface of prostate cancer cells, allowing the drug to deliver radiation from inside the malignancy. This targeted mechanism is supported by molecular-guided imaging, where technicians attach a radioactive tracer to identify cancer cells on PET scans before treatment begins. The integration of this imaging ensures the radiation is delivered with precision to the identified disease sites.
Timeline
Summer 2026: The FDA expanded approval for the treatment Pluvicto.
Health Landscape
This development aligns with the evolving standard of care that favors integrating molecular-guided therapies earlier in treatment pathways. It represents a departure from traditional oncology protocols that reserved such advanced radioactive therapies only after the failure of standard treatments.
Patients currently managing metastatic prostate cancer should consult with their oncology team to determine if updated eligibility criteria make this targeted therapy an appropriate option for their specific condition. It is important to discuss the timing of these treatments relative to current care plans to ensure informed decision-making.
The takeaway
The move to offer targeted, internal radiation therapy earlier in a cancer diagnosis marks a significant evolution in personalized oncology. Patients and their caregivers should monitor their disease markers closely and inquire with their specialist about the latest clinical guidelines for treatment eligibility.
Further reading
To learn more about current diagnostic and therapeutic options for prostate malignancies, visit the Cancer section.
Source note: This article includes information reported by WOODTV.
